Tumor growth inhibition modeling to support the starting dose for dacomitinib
Abstract Dacomitinib is a second‐generation, irreversible EGFR tyrosine kinase inhibitor for first‐line treatment of patients with metastatic non‐small cell lung cancer and EGFR‐activating mutations. A high rate of dose reductions in the pivotal trial led to an observed inverse exposure‐response (ER...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Wiley,
2022-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |